Oral Hairy Leukoplakia: An Unexpected Early Warning Sign of Leukemia
"Could a tongue patch be more than just a harmless anomaly? Learn how oral hairy leukoplakia can sometimes signal a serious underlying condition."
Oral hairy leukoplakia (OHL) is typically associated with the reactivation of the Epstein-Barr virus (EBV), manifesting as distinctive whitish patches, often corrugated or hairy in appearance, primarily on the sides of the tongue. While commonly linked to individuals with compromised immune systems, such as those with AIDS, OHL can also occur in other immunocompromised conditions.
In patients with leukemia, the occurrence of OHL is infrequent and typically arises following chemotherapy treatments. This article highlights a unique instance of OHL serving as the initial sign of acute myeloid leukemia (AML) in a previously healthy 15-year-old child, emphasizing the importance of recognizing such atypical presentations.
This article aims to raise awareness among both the public and healthcare professionals about the potential for OHL to indicate serious underlying conditions, even in the absence of typical risk factors. Early detection can significantly impact treatment outcomes and overall prognosis.
What the Evidence Says About OHL
Oral hairy leukoplakia (OHL) was first described by Greenspan and colleagues in 1984 and typically appears as a whitish patch with a corrugated or hairy surface, most often along the tongue’s lateral borders. A 2025 New England Journal of Medicine report describes it as typically asymptomatic and occurring in immunocompromised patients and older, otherwise healthy people. The supplied sources do not give a global prevalence figure for OHL; the prevalence study cited concerns oral leukoplakia, a distinct condition.
Recognizing and Confirming OHL
OHL should be considered when evaluating leukoplakic lesions on the tongue, regardless of a patient’s HIV status. Its presence can prompt investigation for explanations of Epstein–Barr virus infection, including immunosuppression related to HIV or chronic steroid use. In situ hybridization is described as the gold-standard diagnostic method, although some authors consider a clinical diagnosis possible. The sources therefore identify both a laboratory confirmation method and a debate over relying on clinical features.
A Condition First Described in 1984
Oral hairy leukoplakia was first described in 1984 and is associated with Epstein–Barr virus. Early descriptions linked it mainly to people with HIV, but it can also affect people who are HIV-negative. Its natural history is variable: lesions may appear and disappear spontaneously, and the condition is often asymptomatic. A 2019 comprehensive review notes that OHL rarely requires treatment and may resolve spontaneously.
The Case: When a Tongue Patch Signaled Leukemia
A 15-year-old boy, a soccer player with no prior medical issues, noticed a persistent whitish patch on the left side of his tongue. Initially asymptomatic, the lesion gradually increased in size, prompting medical evaluation. A physical examination revealed corrugated, firmly attached whitish patches that couldn't be easily scraped off.
- Papillomatosis (wart-like growths)
- Hyperkeratosis (thickening of the outer layer of skin)
- Parakeratosis (abnormal keratinization)
- Acanthosis (thickening of the prickle cell layer)
- Ballooning degeneration in the stratum spinosum (a specific layer of the epidermis)
Recent Cases Across Different Conditions
A case report describes a 54-year-old man with polycythemia vera who had non-removable, rough white patches along both lateral borders of the tongue, diagnosed as OHL. In a separate report involving a patient with rheumatism, an ulcer healed four weeks after methotrexate was discontinued, while the hairy leukoplakia thinned. Another listed report concerns OHL in a patient with systemic primary amyloidosis and was published in the International Journal of Oral & Maxillofacial Pathology in 2014, volume 5, issue 3, pages 7–11. These reports illustrate individual cases rather than establishing how often OHL occurs in these conditions.
Trial Evidence Has a Defined Scope
A 2025 analysis of clinical-trial failures in oral leukoplakia explicitly excluded trials addressing oral hairy leukoplakia, along with conditions such as erythroplakia and lichen planus. The report identified 38 clinical trials in total, of which 16 cases and 5 controls met its inclusion criteria. It collected information on trial phase, intervention type, subject accrual, reasons for failure, and sponsorship. Because OHL trials were excluded, these findings cannot be used to explain failures in OHL research.
OHL and Oral Leukoplakia Are Distinct
Oral hairy leukoplakia is described as an Epstein–Barr virus-related lesion that most often appears as corrugated white patches along the lateral tongue. A 2025 New England Journal of Medicine source distinguishes it from other tongue conditions and notes that it can occur in immunocompromised patients and older, otherwise healthy people. By contrast, the 2026 laser-therapy source describes oral leukoplakia as a potentially malignant oral lesion, with variable risk of progression to oral squamous cell carcinoma and challenges related to recurrence and malignant transformation. These sources concern different conditions, so oral leukoplakia treatment findings should not be assumed to describe OHL management.
Why This Case Matters: Recognizing the Unexpected
While OHL is commonly associated with immunosuppression, this case underscores the rare possibility of it being an initial sign of acute myeloid leukemia. Recognizing such atypical presentations is crucial for early diagnosis and intervention.
Testing Potential Risk Markers
A 2026 article on immune suppression and HLA-related risk in oral leukoplakia says larger cohorts and prospective follow-up will be needed to determine whether HLA-related markers can serve as reliable biomarkers for early detection or risk stratification. The source does not establish that these markers are validated, nor does it report them as OHL biomarkers. A 2024 clinical management review likewise notes that predicting high-risk oral leukoplakia remains challenging. Together, the sources point to unresolved questions about risk prediction in oral leukoplakia.
OHL Beyond HIV
OHL commonly presents as an asymptomatic, non-removable white patch on the lateral borders of the tongue in people who are immunocompromised. A case report describes OHL arising in a patient with hairy cell leukemia, showing that the condition has been reported alongside a hematologic disease. The report also notes that OHL was historically thought to be pathognomonic of HIV infection, but is now recognized in a range of conditions. The case illustrates an association in one patient and does not establish OHL as a general early warning sign of leukemia.
This case emphasizes the importance of thorough medical evaluation when encountering unusual oral lesions, especially in individuals without apparent risk factors for immunosuppression. Though rare, considering the possibility of underlying systemic diseases like leukemia can significantly impact patient outcomes.
Although OHL is not generally considered a prognostic indicator except in AIDS, this instance suggests that, when associated with hematologic malignancies, it might indicate an advanced stage or poorer prognosis. This highlights the need for further research to understand the relationship between OHL and leukemia outcomes.